Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Depreciation & Amortization (CF) (2016 - 2022)

Edesa Biotech's Depreciation & Amortization (CF) history spans 10 years, with the latest figure at $28960.0 for Q3 2022.

  • For Q3 2022, Depreciation & Amortization (CF) changed 0.09% year-over-year to $28960.0; the TTM value through Sep 2022 reached $118188.0, down 0.51%, while the annual FY2025 figure was $119273.0, 35.89% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2022 was $28960.0 at Edesa Biotech, down from $29595.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.0 billion in Q2 2020 and bottomed at $412.0 in Q4 2018.
  • The 5-year median for Depreciation & Amortization (CF) is $29020.0 (2020), against an average of $117.2 million.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 94902234.44% in 2020 before it plummeted 100.0% in 2021.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $412.0 in 2018, then soared by 483.25% to $2403.0 in 2019, then soared by 1100.29% to $28843.0 in 2020, then rose by 3.15% to $29752.0 in 2021, then fell by 2.66% to $28960.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Depreciation & Amortization (CF) are $28960.0 (Q3 2022), $29595.0 (Q2 2022), and $29881.0 (Q1 2022).